611 related articles for article (PubMed ID: 32184777)
21. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
22. M1
Garrido-Martin EM; Mellows TWP; Clarke J; Ganesan AP; Wood O; Cazaly A; Seumois G; Chee SJ; Alzetani A; King EV; Hedrick CC; Thomas G; Friedmann PS; Ottensmeier CH; Vijayanand P; Sanchez-Elsner T
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32699181
[TBL] [Abstract][Full Text] [Related]
23. YAP/STAT3 inhibited CD8
Wang C; Shen N; Guo Q; Tan X; He S
Cancer Med; 2023 Aug; 12(15):16295-16309. PubMed ID: 37329188
[TBL] [Abstract][Full Text] [Related]
24. Siglec-9
Wang Y; He M; Zhang C; Cao K; Zhang G; Yang M; Huang Y; Jiang W; Liu H
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37709296
[TBL] [Abstract][Full Text] [Related]
25. Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function.
Cribbs AP; Filippakopoulos P; Philpott M; Wells G; Penn H; Oerum H; Valge-Archer V; Feldmann M; Oppermann U
Front Immunol; 2021; 12():626255. PubMed ID: 33717143
[TBL] [Abstract][Full Text] [Related]
26. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy.
Rodriguez-Garcia A; Lynn RC; Poussin M; Eiva MA; Shaw LC; O'Connor RS; Minutolo NG; Casado-Medrano V; Lopez G; Matsuyama T; Powell DJ
Nat Commun; 2021 Feb; 12(1):877. PubMed ID: 33563975
[TBL] [Abstract][Full Text] [Related]
27. Vinblastine resets tumor-associated macrophages toward M1 phenotype and promotes antitumor immune response.
Wang YN; Wang YY; Wang J; Bai WJ; Miao NJ; Wang J
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37652576
[TBL] [Abstract][Full Text] [Related]
28. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.
Xu HZ; Li TF; Wang C; Ma Y; Liu Y; Zheng MY; Liu ZJ; Chen JB; Li K; Sun SK; Komatsu N; Xu YH; Zhao L; Chen X
J Nanobiotechnology; 2021 Sep; 19(1):268. PubMed ID: 34488792
[TBL] [Abstract][Full Text] [Related]
29. Blockade of DC-SIGN
Hu B; Wang Z; Zeng H; Qi Y; Chen Y; Wang T; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
Cancer Res; 2020 Apr; 80(8):1707-1719. PubMed ID: 32060149
[TBL] [Abstract][Full Text] [Related]
30. CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer.
Marcovecchio PM; Thomas G; Salek-Ardakani S
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637602
[TBL] [Abstract][Full Text] [Related]
31. AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway.
Liu C; Huang Y; Qin T; You L; Lu F; Hu D; Xiao R; Qin X; Guo E; Yang B; Li X; Fan J; Li X; Fu Y; Liu S; Wang Z; Dou Y; Wang W; Li W; Yang X; Liu J; Peng W; Zhang L; Cui Y; Sun C; Chen G
Cancer Lett; 2022 Mar; 528():31-44. PubMed ID: 34942306
[TBL] [Abstract][Full Text] [Related]
32. Tumor-associated macrophages regulate the function of cytotoxic T lymphocyte through PD-1/PD-L1 pathway in multiple myeloma.
Zhang J; Liu Z; Cao P; Wang H; Liu H; Hua L; Xue H; Fu R
Cancer Med; 2022 Dec; 11(24):4838-4848. PubMed ID: 35593325
[TBL] [Abstract][Full Text] [Related]
33. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
34. Extracellular vesicles derived from M2-polarized tumor-associated macrophages promote immune escape in ovarian cancer through NEAT1/miR-101-3p/ZEB1/PD-L1 axis.
Yin L; Wang Y
Cancer Immunol Immunother; 2023 Mar; 72(3):743-758. PubMed ID: 36319716
[TBL] [Abstract][Full Text] [Related]
35. Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy.
Wang YC; Wang X; Yu J; Ma F; Li Z; Zhou Y; Zeng S; Ma X; Li YR; Neal A; Huang J; To A; Clarke N; Memarzadeh S; Pellegrini M; Yang L
Nat Commun; 2021 Jun; 12(1):3530. PubMed ID: 34112755
[TBL] [Abstract][Full Text] [Related]
36. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.
Zeng XY; Xie H; Yuan J; Jiang XY; Yong JH; Zeng D; Dou YY; Xiao SS
Cancer Biol Ther; 2019; 20(7):956-966. PubMed ID: 31062668
[No Abstract] [Full Text] [Related]
37. Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer.
Lu CS; Shiau AL; Su BH; Hsu TS; Wang CT; Su YC; Tsai MS; Feng YH; Tseng YL; Yen YT; Wu CL; Shieh GS
J Hematol Oncol; 2020 Jun; 13(1):62. PubMed ID: 32487125
[TBL] [Abstract][Full Text] [Related]
38. Wnt5a-induced M2 polarization of tumor-associated macrophages via IL-10 promotes colorectal cancer progression.
Liu Q; Yang C; Wang S; Shi D; Wei C; Song J; Lin X; Dou R; Bai J; Xiang Z; Huang S; Liu K; Xiong B
Cell Commun Signal; 2020 Mar; 18(1):51. PubMed ID: 32228612
[TBL] [Abstract][Full Text] [Related]
39. Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles.
Wei Z; Zhang X; Yong T; Bie N; Zhan G; Li X; Liang Q; Li J; Yu J; Huang G; Yan Y; Zhang Z; Zhang B; Gan L; Huang B; Yang X
Nat Commun; 2021 Jan; 12(1):440. PubMed ID: 33469052
[TBL] [Abstract][Full Text] [Related]
40. The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation.
Luo F; Li H; Ma W; Cao J; Chen Q; Lu F; Qiu M; Zhou P; Xia Z; Zeng K; Zhan J; Zhou T; Luo Q; Pan W; Zhang L; Lin C; Huang Y; Zhang L; Yang D; Zhao H
Cell Mol Immunol; 2024 Jan; 21(1):60-79. PubMed ID: 38062129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
